3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
41
SUSRF Quote, Financials, Valuation and Earnings
Last price:
$13.95
Seasonality move
:
-7.01%
Day range:
$13.95 - $13.95
52-week range:
$11.30 - $14.53
Dividend yield:
0%
P/E ratio:
38.79x
P/S ratio:
8.70x
P/B ratio:
1.61x
Volume:
--
Avg. volume:
204
1-year change:
17.82%
Market cap:
$711.8M
Revenue:
$83.4M
EPS (TTM):
$0.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
-- | -- | -- | -- | -- |
|
BOVNF
BioInvent International AB
|
-- | -- | -- | -- | -- |
|
BRCTF
BioArctic AB
|
-- | -- | -- | -- | -- |
|
HNSBF
Hansa Biopharma AB
|
-- | -- | -- | -- | -- |
|
NEVPF
Abliva AB
|
-- | -- | -- | -- | -- |
|
ONPPF
Oncopeptides AB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$13.95 | -- | $711.8M | 38.79x | $0.00 | 0% | 8.70x |
|
BOVNF
BioInvent International AB
|
$4.70 | -- | $309.3M | -- | $0.00 | 0% | 84.18x |
|
BRCTF
BioArctic AB
|
$19.32 | -- | $1.7B | -- | $0.00 | 0% | 107.08x |
|
HNSBF
Hansa Biopharma AB
|
$3.00 | -- | $196.8M | -- | $0.00 | 0% | 9.81x |
|
NEVPF
Abliva AB
|
$0.04 | -- | $58M | -- | $0.00 | 0% | -- |
|
ONPPF
Oncopeptides AB
|
$0.27 | -- | $24M | -- | $0.00 | 0% | 8.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
-- | 0.028 | -- | 3.73x |
|
BOVNF
BioInvent International AB
|
-- | 0.000 | -- | 13.16x |
|
BRCTF
BioArctic AB
|
-- | 1.787 | -- | 5.10x |
|
HNSBF
Hansa Biopharma AB
|
151.36% | -0.207 | 48.65% | 2.44x |
|
NEVPF
Abliva AB
|
-- | -11.572 | -- | -- |
|
ONPPF
Oncopeptides AB
|
-- | -1.624 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUSRF
Surgical Science Sweden AB
|
$15.5M | $4.4M | 4.27% | 4.27% | 19.75% | $1M |
|
BOVNF
BioInvent International AB
|
-- | -$10.3M | -33.69% | -33.69% | -839.44% | -$10M |
|
BRCTF
BioArctic AB
|
$6.6M | -$2.5M | -23.03% | -23.03% | -24.9% | -$8.3M |
|
HNSBF
Hansa Biopharma AB
|
$3.6M | -$11.3M | -95.02% | -- | -240.28% | -$15.3M |
|
NEVPF
Abliva AB
|
-- | -$1.9M | -- | -- | -- | -$3.8M |
|
ONPPF
Oncopeptides AB
|
-- | -- | -- | -- | -- | -- |
Surgical Science Sweden AB vs. Competitors
-
Which has Higher Returns SUSRF or BOVNF?
BioInvent International AB has a net margin of 18.56% compared to Surgical Science Sweden AB's net margin of -761.85%. Surgical Science Sweden AB's return on equity of 4.27% beat BioInvent International AB's return on equity of -33.69%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB69.45% $0.08 $441.3M BOVNFBioInvent International AB-- -$0.14 $99.5M -
What do Analysts Say About SUSRF or BOVNF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioInvent International AB, analysts believe Surgical Science Sweden AB is more attractive than BioInvent International AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BOVNFBioInvent International AB0 0 0 -
Is SUSRF or BOVNF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.276%.
-
Which is a Better Dividend Stock SUSRF or BOVNF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BOVNF?
Surgical Science Sweden AB quarterly revenues are $22.3M, which are larger than BioInvent International AB quarterly revenues of $1.2M. Surgical Science Sweden AB's net income of $4.1M is higher than BioInvent International AB's net income of -$9.4M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 38.79x while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 8.70x versus 84.18x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB8.70x 38.79x $22.3M $4.1M BOVNFBioInvent International AB84.18x -- $1.2M -$9.4M
-
Which has Higher Returns SUSRF or BRCTF?
BioArctic AB has a net margin of 18.56% compared to Surgical Science Sweden AB's net margin of -25.62%. Surgical Science Sweden AB's return on equity of 4.27% beat BioArctic AB's return on equity of -23.03%.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB69.45% $0.08 $441.3M BRCTFBioArctic AB89.45% -$0.02 $91.1M -
What do Analysts Say About SUSRF or BRCTF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than BioArctic AB, analysts believe Surgical Science Sweden AB is more attractive than BioArctic AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 BRCTFBioArctic AB0 0 0 -
Is SUSRF or BRCTF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SUSRF or BRCTF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or BRCTF?
Surgical Science Sweden AB quarterly revenues are $22.3M, which are larger than BioArctic AB quarterly revenues of $7.4M. Surgical Science Sweden AB's net income of $4.1M is higher than BioArctic AB's net income of -$1.9M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 38.79x while BioArctic AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 8.70x versus 107.08x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB8.70x 38.79x $22.3M $4.1M BRCTFBioArctic AB107.08x -- $7.4M -$1.9M
-
Which has Higher Returns SUSRF or HNSBF?
Hansa Biopharma AB has a net margin of 18.56% compared to Surgical Science Sweden AB's net margin of -213.29%. Surgical Science Sweden AB's return on equity of 4.27% beat Hansa Biopharma AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB69.45% $0.08 $441.3M HNSBFHansa Biopharma AB76.62% -$0.15 $61.8M -
What do Analysts Say About SUSRF or HNSBF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Hansa Biopharma AB, analysts believe Surgical Science Sweden AB is more attractive than Hansa Biopharma AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 HNSBFHansa Biopharma AB0 0 0 -
Is SUSRF or HNSBF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.431%.
-
Which is a Better Dividend Stock SUSRF or HNSBF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or HNSBF?
Surgical Science Sweden AB quarterly revenues are $22.3M, which are larger than Hansa Biopharma AB quarterly revenues of $4.7M. Surgical Science Sweden AB's net income of $4.1M is higher than Hansa Biopharma AB's net income of -$10M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 38.79x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 8.70x versus 9.81x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB8.70x 38.79x $22.3M $4.1M HNSBFHansa Biopharma AB9.81x -- $4.7M -$10M
-
Which has Higher Returns SUSRF or NEVPF?
Abliva AB has a net margin of 18.56% compared to Surgical Science Sweden AB's net margin of --. Surgical Science Sweden AB's return on equity of 4.27% beat Abliva AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB69.45% $0.08 $441.3M NEVPFAbliva AB-- -$0.00 -- -
What do Analysts Say About SUSRF or NEVPF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Abliva AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Abliva AB, analysts believe Surgical Science Sweden AB is more attractive than Abliva AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 NEVPFAbliva AB0 0 0 -
Is SUSRF or NEVPF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abliva AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SUSRF or NEVPF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abliva AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Abliva AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or NEVPF?
Surgical Science Sweden AB quarterly revenues are $22.3M, which are larger than Abliva AB quarterly revenues of --. Surgical Science Sweden AB's net income of $4.1M is higher than Abliva AB's net income of -$1.9M. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 38.79x while Abliva AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 8.70x versus -- for Abliva AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB8.70x 38.79x $22.3M $4.1M NEVPFAbliva AB-- -- -- -$1.9M
-
Which has Higher Returns SUSRF or ONPPF?
Oncopeptides AB has a net margin of 18.56% compared to Surgical Science Sweden AB's net margin of --. Surgical Science Sweden AB's return on equity of 4.27% beat Oncopeptides AB's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUSRFSurgical Science Sweden AB69.45% $0.08 $441.3M ONPPFOncopeptides AB-- -- -- -
What do Analysts Say About SUSRF or ONPPF?
Surgical Science Sweden AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncopeptides AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgical Science Sweden AB has higher upside potential than Oncopeptides AB, analysts believe Surgical Science Sweden AB is more attractive than Oncopeptides AB.
Company Buy Ratings Hold Ratings Sell Ratings SUSRFSurgical Science Sweden AB0 0 0 ONPPFOncopeptides AB0 0 0 -
Is SUSRF or ONPPF More Risky?
Surgical Science Sweden AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncopeptides AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SUSRF or ONPPF?
Surgical Science Sweden AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncopeptides AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgical Science Sweden AB pays -- of its earnings as a dividend. Oncopeptides AB pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUSRF or ONPPF?
Surgical Science Sweden AB quarterly revenues are $22.3M, which are larger than Oncopeptides AB quarterly revenues of --. Surgical Science Sweden AB's net income of $4.1M is higher than Oncopeptides AB's net income of --. Notably, Surgical Science Sweden AB's price-to-earnings ratio is 38.79x while Oncopeptides AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgical Science Sweden AB is 8.70x versus 8.28x for Oncopeptides AB. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUSRFSurgical Science Sweden AB8.70x 38.79x $22.3M $4.1M ONPPFOncopeptides AB8.28x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
